To evaluate the effects of ocriplasmin and symptomatic vitreomacular adhesion resolution on visual fixation and macular sensitivity using microperimetry.
MP-1 parameters were analyzed from 3 OASIS sites after the use of standardized instruments and testing procedures over 24 months.
A total of 27 patients (19 ocriplasmin, 8 sham) were evaluated. Mean distance of the preferred fixation locus to the anatomical center was farther in the sham group at baseline and farther in the sham versus ocriplasmin group throughout the study. Retinal sensitivity values were consistently higher in the ocriplasmin versus sham group after Month 3. Fewer patients in the ocriplasmin group had predominantly eccentric fixation at study end compared with the sham group, which also had an increased number of patients with unstable fixation. Patients with vitreomacular adhesion resolution had lower bivariate contour area, fewer relative scotomas, and higher retinal sensitivity parameters at baseline than those with unresolved vitreomacular adhesion.
Substudy results suggest that fixation and sensitivity parameters tended to be better in the ocriplasmin group than in the sham group over time. The substudy identified parameters that were distinct between patients with and without vitreomacular adhesion resolution, suggesting that microperimetry warrants further study as a relevant biomarker for visual function.
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
The MP-1 substudy of the OASIS trial evaluated the effects of ocriplasmin and symptomatic VMA resolution on visual fixation and macular sensitivity using microperimetry, identifying parameters that were distinct between patients with and without VMA resolution.
*Doheny Eye Institute, University of California, Los Angeles, California;
†USC Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California;
‡Retinal Consultants of Arizona LTD, Retinal Research Institute LLC, Phoenix, Arizona;
§Phoenix Eye Institute, Banner University Medical Center, Phoenix, Arizona;
‖Valley Retina Institute, P.A., McAllen, Texas; and
¶ThromboGenics NV, Leuven, Belgium.
Reprint requests: SriniVas R. Sadda, MD, 1355 San Pablo Street, DVRC 211 Los Angeles, CA 90033; e-mail: Sadda@doheny.org
The authors have received funding from ThromboGenics, Iselin, New Jersey. The sponsor or funding organization participated in the design of the study, conducting the study, data collection, data management, data analysis, interpretation of the data, preparation, and review or approval of the manuscript.
S. R. Sadda is a consultant and receives research support from Optos, Carl Zeiss Meditech, Allergan, and Genentech and is a consultant for ThromboGenics Inc, Regeneron, and Novartis. P. U. Dugel is a consultant for Abbott/AMO, Aerpio, Alcon, Alimera Sciences, Allergan, Annidis, Acucela, ArcticAx, Avalanche Biotechnologies, Clearside Biomedical, Digisight, DOSE Medical, Genentech, Lutronic, Lux BioScience, Novartis, OD-OS, Omeros, Ophthotech, Opthea, Optovue, ORA, Regeneron, Roche, Pentavision, Shire Human Genetic Therapies, Stealth BioTherapeutics, ThromboGenics Inc, TopCon and is a minor stock shareholder in Alimera, Aerpio, Annidis, Digisight, Neurotech, TrueVision. V. H. Gonzalez is a consultant and receives research support from Genentech, Regeneron, ThromboGenics Inc, Alcon, Allergan, Alimera Sciences, and Valeant is a consultant for Bayer and Bausch + Lomb, and receives research support from Kalvista, Panoptica, Santen, Iconic Therapeutics, Ophthotech, Merck, Allegro Ophthalmics, Ohr Pharmaceutical Inc, Eyegate Pharmaceuticals, Inc, Astellas Pharma Europe B.V., DRCR.NET. E. Meunier is employed as a consultant by ThromboGenics Inc. P. Kozma reports personal fees from ThromboGenics, outside of the submitted work.